SKIP TO
CONTENT
"*" indicates required fields
By clicking SUBMIT you agree to our Terms of Use and Privacy Policy and you are providing express consent to receive communications from Berger Montague via calls, emails, and/or text messages.
Practice Area: Securities Fraud & Investor Protection
Case Status: Pending
Ticker Symbol: NASDAQ: RARE
Investigation Deadline: April 6, 2026
A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023 through December 26, 2025 (the “Class Period”).
Investor Deadline: Investors who purchased Ultragenyx common stock during the Class Period may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class.
If you are a Ultragenyx investor and would like to learn more about this action, please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
Ultragenyx is a biopharmaceutical company that acquires and develops novel products for treatment of rare genetic diseases. It is headquartered in Novato, Calif.
According to the lawsuit, throughout the Class Period, defendants issued overwhelmingly positive statements to investors concerning the ORBIT and COSMIC Phase 3 programs, clinical trials to test setrusumab as a treatment for Osteogenesis Imperfecta.
When, on December 29, 2025, Ultragenyx disclosed that neither study achieved its primary endpoint of reducing the annualized clinical fracture rate, the price of its shares dropped more than 42%, from a closing price of $34.19 per share on December 26, 2025 to a close of $19.72 per share on December 29, 2025.
Director of Portfolio and Institutional Client Monitoring Services
